Skip to main content

Table 2 Association of different PUFAs concentrations with the risk of CHD, heart attack, CHF, stroke, and angina

From: Associations of polyunsaturated fatty acids with cardiovascular disease and mortality: a study of NHANES database in 2003–2018

PUFAs level

CHD

Heart attack

CHF

Stroke

Angina

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

ODA

  ≤ Q1

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

 Q1-Q2

1.17 (0.94–1.46)

0.154

1.03 (0.85–1.24)

0.785

0.86 (0.71–1.04)

0.125

0.91 (0.75–1.10)

0.330

0.87 (0.65–1.15)

0.327

 Q2-Q3

1.05 (0.80–1.38)

0.721

1.03 (0.77–1.37)

0.831

0.68 (0.54–0.86)

0.001

0.77 (0.59–1.01)

0.063

1.02 (0.76–1.37)

0.884

  > Q3

1.15 (0.79–1.66)

0.463

0.97 (0.67–1.41)

0.888

0.66 (0.49–0.90)

0.009

0.65 (0.47–0.90)

0.009

1.02 (0.69–1.50)

0.915

ALA

  ≤ Q1

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

 Q1-Q2

0.86 (0.69–1.07)

0.176

0.81 (0.66–0.99)

0.043

1.02 (0.80–1.29)

0.893

0.96 (0.78–1.19)

0.717

0.96 (0.75–1.24)

0.758

 Q2-Q3

0.81 (0.63–1.05)

0.117

0.73 (0.53–1.01)

0.058

1.07 (0.82–1.39)

0.624

0.90 (0.69–1.16)

0.402

0.86 (0.63–1.17)

0.328

  > Q3

0.74 (0.53–1.04)

0.079

0.72 (0.50–1.04)

0.079

1.39 (0.99–1.94)

0.057

1.03 (0.75–1.42)

0.836

0.77 (0.52–1.13)

0.178

ODTA

 No

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

 Yes

0.75 (0.64–0.88)

 < 0.001

0.90 (0.76–1.06)

0.198

0.91 (0.74–1.12)

0.368

0.87 (0.71–1.08)

0.202

0.82 (0.66–1.02)

0.069

AA

  ≤ Q1

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

 Q1-Q2

0.98 (0.81–1.18)

0.814

0.95 (0.77–1.17)

0.642

0.86 (0.69–1.07)

0.179

1.06 (0.87–1.29)

0.585

0.86 (0.67–1.10)

0.219

 Q2-Q3

1.00 (0.79–1.27)

0.989

1.05 (0.79–1.39)

0.758

1.10 (0.86–1.40)

0.442

1.22 (0.97–1.54)

0.094

0.96 (0.71–1.30)

0.811

  > Q3

0.90 (0.67–1.20)

0.463

1.01 (0.77–1.33)

0.942

1.07 (0.80–1.42)

0.653

1.04 (0.76–1.43)

0.817

0.94 (0.66–1.35)

0.741

EPA

  ≤ Q1

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

 Q1-Q2

1.06 (0.89–1.27)

0.491

1.03 (0.84–1.26)

0.767

0.94 (0.76–1.14)

0.511

0.85 (0.68–1.06)

0.141

1.03 (0.82–1.29)

0.794

 Q2-Q3

0.90 (0.72–1.13)

0.353

1.02 (0.83–1.27)

0.828

0.80 (0.62–1.04)

0.096

1.09 (0.85–1.39)

0.488

1.10 (0.80–1.52)

0.562

  > Q3

1.30 (0.94–1.79)

0.114

1.12 (0.83–1.51)

0.468

0.93 (0.69–1.26)

0.648

0.92 (0.69–1.24)

0.594

1.40 (0.95–2.07)

0.092

DPA

  ≤ Q1

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

 Q1-Q2

1.07 (0.85–1.33)

0.576

0.83 (0.68–1.02)

0.070

0.95 (0.75–1.20)

0.658

0.81 (0.64–1.03)

0.087

0.80 (0.60–1.07)

0.132

 Q2-Q3

0.99 (0.81–1.22)

0.959

0.78 (0.62–0.99)

0.037

0.86 (0.66–1.13)

0.282

0.78 (0.59–1.03)

0.075

0.76 (0.58–0.99)

0.043

  > Q3

1.12 (0.82–1.53)

0.458

0.84 (0.62–1.13)

0.248

0.99 (0.71–1.38)

0.956

0.94 (0.69–1.29)

0.699

0.85 (0.59–1.22)

0.368

DHA

  ≤ Q1

Ref

 

Ref

 

Ref

 

Ref

 

Ref

 

 Q1-Q2

0.89 (0.70–1.13)

0.334

0.91 (0.71–1.17)

0.482

1.10 (0.89–1.36)

0.388

1.04 (0.84–1.29)

0.727

0.90 (0.67–1.21)

0.492

 Q2-Q3

0.95 (0.73–1.23)

0.687

1.05 (0.80–1.38)

0.722

1.14 (0.89–1.46)

0.292

1.05 (0.81–1.36)

0.708

0.98 (0.71–1.35)

0.904

  > Q3

0.73 (0.51–1.04)

0.083

1.00 (0.70–1.45)

0.980

0.85 (0.61–1.19)

0.336

1.03 (0.75–1.40)

0.870

0.80 (0.55–1.16)

0.240

  1. PUFA Polyunsaturated fatty acid, CHD Coronary heart disease, CHF Congestive heart failure, OR Odds ratio, CI Confidence interval, ODA Octadecadienoic acid, Ref: Reference, ALA Octadecatrienoic acid, ODTA Octadecatetraenoic acid, AA Eicosatetraenoic acid, EPA eicosapentaenoic acid, DPA Docosapentaenoic acid, DHA: Docosahexaenoic acid
  2. Model 1 was the crude model;
  3. Model 2 adjusted for age, gender, race, education level, marital status, PIR, BMI, physical activity, hypertension, DM, smoking, drinking, total energy intake;
  4. Model 3 adjusted for covariates adjusted in Model 2 as well as different PUFAs (excluded the one for analysis)
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us